To learn more about each vacancy, click on the relevant link below. If you
don't see a vacancy that interests you today, please visit this site soon
to check for more job postings or send us an open application.
Kiadis Pharma announces collaboration with the Julius Maximilians University of Würzburg, Germany. Dr. Mielke continues his collaboration with Kiadis Pharma on ATIR™
May 29th 2008
Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR™ with Dr. Stephan Mielke and...
read more 
(NL version)
(NL version)
Kiadis Pharma receives Orphan Drug Designation for Rhitol™ from the FDA
Apr 15th 2008
Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol™ Orphan Drug...
read more (NL version)
(NL version)
- Kiadis Pharma obtains FDA approval to start a phase III clinical trial for Reviroc™ in the United States. FDA approves IND application for Reviroc™ - Feb 22nd 2008 (NL)
- Kiadis Pharma announces successful completion of Rhitol™ Phase II clinical study - Jan 31st 2008 (NL)
- Kiadis Pharma reports successful End of Phase II Meeting with FDA for Reviroc; the FDA offers Special Protocol Assesment for Reviroc - Dec 19th 2007 (NL)
- ATIR classified as “cell based” medicinal product by the EMEA; a classification for innovative new treatments - Dec 14th 2007 (NL)
- Promising data ATIR studies presented by NIH Investigators - Nov 28th 2007 (NL)
1098 VA Amsterdam
The Netherlands
t +31 (0)20 888 48 15
f +31 (0)20 888 48 63
Zernikepark 6-8
9747 AN Groningen
The Netherlands
t +31 (0) 50 547 42 70
f +31 (0) 50 547 42 71
2525 ave. Marie-Curie
Saint-Laurent (Quebec)
Canada H4S 2E1
t +1 (514) 336-4886
f +1 (514) 336-7329